TGA-approved drug hits global snag

By Megan Brodie 1 year ago | In Products, Regulatory
  • 1 year ago

14 November 2022 Swiss biotech Helsinn has withdrawn its first-in-class rare cancer drug from regulatory…

This is subscriber-only content. Please login to continue reading.

Recent News

Top Reads